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therapy change, meaning that other approaches should 
be preferred as first-line therapy.
Numerous studies have analysed the clinical activity 
of extracorporeal photochemotherapy in patients with 
cutaneous T-cell lymphoma, although the majority are 
retrospective or single-centre and include relatively small 
patient cohorts. The proportions of patients achieving a 
response range between 33% and more than 90%, with 
mean values of 63% with complete responses in about 
20% of cases.7
Two randomised studies8,9 have documented the 
clinical efficacy of new drugs brentuximab vedotin and 
mogamulizumab in pretreated patients with cutaneous 
T-cell lymphoma. In the ALCANZA trial,8 a randomised 
phase 3 trial comparing brentuximab vedotin versus 
methotrexate or bexarotene in CD30-positive mycosis 
fungoides or primary cuta- neous anaplastic large-
cell lymphoma, patients with high blood Sézary cell 
counts were not included; however, the clinical activity 
of brentuximab vedotin has been reported in patients 
with Sézary syndrome in previous phase 2 studies. 
In the MAVORIC trial,9 a phase 3 randomised trial 
comparing the anti-CCR4 antibody mogamulizumab 
with vorinostat, the proportion of patients with a 
response in the blood was 68% and global responses in 
Sézary syndrome occurred in 30 (37%) of 81 patients. 
The median duration of response in the blood was 
25·5 months (IQR 15·9–not estimable) and in the skin 
20·6 months (11·2–not estimable), with 36 (20%) 
of 184 patients developing serious adverse events 
considered treatment related.
The results reported by Bagot and colleagues1 in this 
phase 1 study of IPH4102 are encouraging. However, they 
need to be confirmed in phase 2 and 3 trials, together 
with the identification of parameters associated with a 
better clinical activity that could drive patient selection. 
Future studies could also attempt to ascertain the 
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The human body is home to several niche-specific 
microbial communities (termed microbiota), which, 
through host–microbe networking, are thought to 
have an integral role in human physiology. Many 
observational studies have shown differences in terms 
of the composition of bacterial microbiota (and much 
less frequently of viral and fungal microbiota) between 
healthy people and those presenting with various 
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position of this treatment in the treatment of patients 
with Sézary syndrome. At the moment, we could 
speculatively adopt this targeted approach in patients 
refractory to, or who have relapsed after, extracorporeal 
photochemotherapy, but also in association with it or even 
before, particularly in patients with a large tumour burden 
in the peripheral blood who are less responsive to standard 
therapies. Moreover, similarly to mogamulizumab, 
IPH4102 could also be considered as a bridge to allo 
transplant in young candidate patients.
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conditions.1 Such differences are postulated to suggest 
that dysregulation of microbiota–host interactions 
(termed dysbiosis) is a putative disease mechanism in 
a myriad of conditions. Although most microbiome-
wide studies so far, including those done in oncology, 
have been cross-sectional, which precludes the 
deduction of causal inferences and means that 
the findings are prone to bias and confounding, the 
human microbiota could nevertheless be a promising 
target for various aspects of cancer prevention and 
treatment.1
In The Lancet Oncology, Nuno Nené and colleagues2 
report the findings of a case-control study in which 
they used 16S rRNA gene sequencing to characterise 
the cervicovaginal microbiota, which was sampled 
in women with epithelial ovarian cancer before 
treatment (the ovarian cancer set) and women with 
the BRCA1 mutation in whom ovarian cancer had 
not yet developed (the BRCA set). Both sets were 
matched with a mixture of healthy controls and 
controls with benign gynaecological conditions. 
Among the 85 participants younger than 50 years 
of age in the ovarian cancer set (69 [81%] of whom 
were premenopausal), cases with ovarian cancer 
were more likely to present with a community type O 
cervicovaginal microbiota (ie, one in which lactobacilli 
accounted for less than 50% of the total bacteria 
present) than were age-matched controls, after 
adjustment for a set of key covariables (adjusted odds 
ratio 2·80 [95% CI 1·17–6·94]).
Nené and colleagues’ decision to dichotomise 
cervicovaginal microbiota status with a 0·5 rank 
abundance cutoff for lactobacilli (ie, <50% lactobacilli 
vs ≥50% lactobacilli) is unconventional but pragmatic. 
In most populations, the vaginal microbiota in women 
of reproductive-age is largely dominated by niche-
specific lactobacilli,3 and deviation from this state is 
associated with a range of adverse reproductive health 
outcomes.4 However, the vagina is also a highly dynamic 
ecosystem,3,4 and by assessing the microbiota on only 
one occasion, there is a risk of misclassification bias in 
the authors’ findings.
Irrespective of these and other methodological 
issues, such as the cross-sectional design of the study, 
the highly novel findings presented by Nené and 
colleagues2 beg the question as to how the vaginal 
microbiota relate to ovarian neoplasia. Vaginal 
microbiota status could be a proxy variable reflecting 
the plasticity of the microbiota to extrinsic factors 
that are potentially involved in ovarian carcinogenesis, 
albeit through non-microbial pathways—for example, 
smoking is assumed to negatively affect lactobacillus 
dominance,5 whereas by contrast oestrogen-based 
hormonal contraception and hormone replacement 
therapy are thought to enhance it.5 More direct, 
mechanistic associations should also be considered. 
Banerjee and colleagues6 have described a fairly 
consistent ovarian microbiota signature that is 
associated with ovarian cancer. Although these 
associations could also be a consequence of reverse 
causation (ie, cancer leading to microbiota alterations 
in the tumour environment), and the origins of the 
ovarian microbiota remain elusive, some researchers 
have suggested that the vaginal microbiota acts as 
a so-called microbial seed bank for the upper genital 
tract.7 Biofilm-associated vaginal dysbiosis can ascend 
to the endometrial cavity and fallopian tubes,8 and 
such a process could hypothetically have a role in the 
complex, extra-ovarian origins of ovarian epithelial 
cancers. Notably, pelvic inflammatory disease, the 
key clinical example of ascending female genital tract 
infection, is cautiously thought to be a potential risk 
factor in ovarian cancer.9
Less obvious mechanisms could also be involved in 
the relationship between cervicovaginal microbiota 
and ovarian cancer. Of particular interest in this respect 
was Nené and colleagues’ finding that BRCA1 mutation 
carriers aged younger than 50 years were also more likely 
to have community type O (ie, lactobacilli-depleted) 
cervicovaginal microbiota relative to controls wild 
type for BRCA1 (odds ratio 2·79 [95% CI 1·25–6·68] 
after adjustment for pregnancy [ever]).2 Assembly of 
tissue-associated microbiota is co-driven by the human 
genome, which possibly explains why loss-of-function 
mutations in tumour genes have been associated with 
composition of the gut microbiota.10 Although only 
10–15% of women with incident ovarian cancers have a 
BRCA1 mutation,9 the associations between end-organ 
cancer, BRCA1 mutation, and dysbiosis of anatomically 
distant but possibly related microbiota highlight the 
complexities of ovarian carcinogenesis and disentangling 
the roles of known risk factors in the process.
Accordingly, rather than making a case for probiotic 
treatment, as suggested by the authors, these findings 
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Cancer and night shift work: what we still do not know 
and why
The International Agency for Research on Cancer 
(IARC) have categorised night shift work as probably 
carcinogenic to humans.1 This news is potentially 
concerning—but what does this assessment mean and, 
perhaps more importantly, what does it not mean?
Like all such IARC categorisations, it tells us nothing 
at all about the actual risks to night shift workers. The 
assessments weigh up the strength of evidence that there 
could be a potential risk under certain circumstances. 
Whether in practice there is an actual risk, and if so, 
how big that risk is, is something that the IARC does 
not consider in deciding the category. This distinction 
is made clear in the Q&A document2 that they released. 
Their conclusion is that night shift work probably can 
increase the risk of cancer in humans under certain 
circumstances—that is exactly what they mean by 
“probably carcinogenic to humans”. But they do not state 
which circumstances or how much increased risk. And, 
because they say “probably”, there remains a possibility 
that shift work cannot affect human cancer risk at all. 
The classifications that IARC uses for things that 
potentially could cause cancer are broad. They have 
just four categories for everything they investigate. 
The “probably” category currently contains 82 different 
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underline the need for systems biology approaches 
in ovarian cancer research. It is a common fallacy to 
infer from documentation of differing microbiota that 
restoration of eubiosis (if possible) will affect disease 
onset or course. Overall, there is no direct evidence 
that the human microbiota has a key role in cancer 
causation, but the microbiota needs to be taken into 
account in future research.1 The challenging but essential 
task now is to seek confirmation in related studies, and 
to elucidate how host genetic, epigenetic, microbiota, 
reproductive, lifestyle, and other environmental factors 
converge in ovarian neoplasia, a highly heterogeneous 
disease.9
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